103 related articles for article (PubMed ID: 30761959)
1. Higher Anti-angiogenesis Activity, Better Cellular Uptake and Longer Half-life of a Novel Glyco-modified Endostatin by Polysulfated Heparin.
Sun F; Shaikh AS; Wang J; Gao H; Yang Z; Wang Z; Li Y; Wang F; Tan H
Curr Pharm Biotechnol; 2018; 19(12):996-1004. PubMed ID: 30761959
[TBL] [Abstract][Full Text] [Related]
2. Preparation, characterization and anti-angiogenesis activity of endostatin covalently modified by polysulfated heparin.
Ning TH; Chao CJ; Ying MG; Min X; Shan WF
Pharmazie; 2012 Jul; 67(7):622-7. PubMed ID: 22888520
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium derived factor make low molecular weight heparin-endostatin and polyethylene glycol-endostatin potential candidates for anti-angiogenesis drug.
Tan H; Mu G; Zhu W; Liu J; Wang F
Biol Pharm Bull; 2011; 34(4):545-50. PubMed ID: 21467643
[TBL] [Abstract][Full Text] [Related]
4. Characterization, bioactivity and pharmacokinetic study of a novel carbohydrate-peptide polymer: Glycol-split heparin-endostatin2 (GSHP-ES2).
Sun F; Wang Z; Yang Z; Li Y; Cui H; Liu C; Gao D; Wang F; Tan H
Carbohydr Polym; 2019 Mar; 207():79-90. PubMed ID: 30600066
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.
Bai Y; Zhao M; Zhang C; Li S; Qi Y; Wang B; Huang L; Li X
PLoS One; 2014; 9(11):e112448. PubMed ID: 25380141
[TBL] [Abstract][Full Text] [Related]
6. Enhanced anti-angiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin.
Tan H; Yang S; Liu C; Cao J; Mu G; Wang F
Biomed Pharmacother; 2012 Dec; 66(8):648-54. PubMed ID: 23122594
[TBL] [Abstract][Full Text] [Related]
7. Augmented anti-angiogenesis activity of polysulfated heparin-endostatin and polyethylene glycol-endostatin in alkali burn-induced corneal ulcers in rabbits.
Li ZN; Yuan ZF; Mu GY; Hu M; Cao LJ; Zhang YL; Ge MX
Exp Ther Med; 2015 Sep; 10(3):889-894. PubMed ID: 26622410
[TBL] [Abstract][Full Text] [Related]
8. Study on glyco-modification of endostatin-derived synthetic peptide endostatin2 (ES2) by soluble chitooligosaccharide.
Yu Y; Sun F; Zhang C; Wang Z; Liu J; Tan H
Carbohydr Polym; 2016 Dec; 154():204-13. PubMed ID: 27577911
[TBL] [Abstract][Full Text] [Related]
9. Characterization and secondary structure analysis of endostatin covalently modified by polyethylene glycol and low molecular weight heparin.
Tan H; Yang S; Feng Y; Liu C; Cao J; Mu G; Wang F
J Biochem; 2008 Aug; 144(2):207-13. PubMed ID: 18463113
[TBL] [Abstract][Full Text] [Related]
10. Endostatin derivative angiogenesis inhibitors.
Zheng MJ
Chin Med J (Engl); 2009 Aug; 122(16):1947-51. PubMed ID: 19781376
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of polysulfated heparin endostatin on alkali burn induced corneal neovascularization in rabbits.
Li ZN; Yuan ZF; Mu GY; Hu M; Cao LJ; Zhang YL; Liu L; Ge MX
Int J Ophthalmol; 2015; 8(2):234-8. PubMed ID: 25938033
[TBL] [Abstract][Full Text] [Related]
12. Tat PTD-endostatin: A novel anti-angiogenesis protein with ocular barrier permeability via eye-drops.
Zhang X; Li Y; Cheng Y; Tan H; Li Z; Qu Y; Mu G; Wang F
Biochim Biophys Acta; 2015 Jun; 1850(6):1140-9. PubMed ID: 25662072
[TBL] [Abstract][Full Text] [Related]
13. The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin.
Lim J; Duong T; Lee G; Seong BL; El-Rifai W; Ruley HE; Jo D
Biomaterials; 2013 Aug; 34(26):6261-71. PubMed ID: 23714245
[TBL] [Abstract][Full Text] [Related]
14. Engineering of a disulfide loop instead of a Zn binding loop restores the anti-proliferative, anti-angiogenic and anti-tumor activities of the N-terminal fragment of endostatin: Mechanistic and therapeutic insights.
Chamani R; Asghari SM; Alizadeh AM; Eskandari S; Mansouri K; Khodarahmi R; Taghdir M; Heidari Z; Gorji A; Aliakbar A; Ranjbar B; Khajeh K
Vascul Pharmacol; 2015 Sep; 72():73-82. PubMed ID: 26187352
[TBL] [Abstract][Full Text] [Related]
15. Soluble multimer of recombinant endostatin expressed in E. coli has anti-angiogenesis activity.
Wei DM; Gao Y; Cao XR; Zhu NC; Liang JF; Xie WP; Zhen MY; Zhu MS
Biochem Biophys Res Commun; 2006 Jul; 345(4):1398-404. PubMed ID: 16723120
[TBL] [Abstract][Full Text] [Related]
16. The antiangiogenic and antitumor activities of the N-terminal fragment of endostatin augmented by Ile/Arg substitution: The overall structure implicated the biological activity.
Chamani R; Asghari SM; Alizadeh AM; Mansouri K; Doroudi T; Kolivand PH; Ghafouri H; Ehtesham S; Rabouti H; Mehrnejad F
Biochim Biophys Acta; 2016 Dec; 1864(12):1765-1774. PubMed ID: 27693049
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effect of local injectable hydrogel-loaded endostatin alone and in combination with radiotherapy for lung cancer.
Wang N; Gao Q; Tang J; Jiang Y; Yang L; Shi X; Chen Y; Zhang Y; Fu S; Lin S
Drug Deliv; 2021 Dec; 28(1):183-194. PubMed ID: 33427520
[TBL] [Abstract][Full Text] [Related]
18. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid.
Alam F; Al-Hilal TA; Chung SW; Seo D; Mahmud F; Kim HS; Kim SY; Byun Y
Biomaterials; 2014 Aug; 35(24):6543-52. PubMed ID: 24816287
[TBL] [Abstract][Full Text] [Related]
19. Effect of RGD-4C position is more important than disulfide bonds on antiangiogenic activity of RGD-4C modified endostatin derived synthetic polypeptide.
Yin R; Zheng H; Xi T; Xu HM
Bioconjug Chem; 2010 Jul; 21(7):1142-7. PubMed ID: 20515045
[TBL] [Abstract][Full Text] [Related]
20. Simulation of tumor-induced angiogenesis and its response to anti-angiogenic drug treatment: mode of drug delivery and clearance rate dependencies.
Tee D; DiStefano J
J Cancer Res Clin Oncol; 2004 Jan; 130(1):15-24. PubMed ID: 14586644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
